Efficacy of either PD-1 inhibitor monotherapy or combined PD-1 inhibitor and ipilimumab (an anti-CTLA-4 monoclonal antibody) in patients with disease metastatic uveal melanoma.
Latest Information Update: 21 Sep 2017
Price :
$35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 21 Sep 2017 New trial record
- 01 Sep 2017 Results assessing the efficacy of of either PD-1 inhibitor Pembrolizumab and Nivolumab monotherapy or combined PD-1 inhibitor and ipilimumab in patients with disease metastatic uveal melanoma, were published in the European Journal of Cancer.